| 1 |
Weber B, Guo XH, Wraith JE, Cooper A, Kleijer WJ, Bunge S, et al. Novel mutations in Sanfilippo A syndrome: implications for enzyme function. Hum Mol Genet 1997;6:1573-9.
DOI
|
| 2 |
Di Natale P, Balzano N, Esposito S, Villani GR. Identification of molecular defects in Italian Sanfilippo A patients including 13 novel mutations. Hum Mutat 1998;11:313-20.
DOI
|
| 3 |
Montfort M, Vilageliu L, Garcia-Giralt N, Guidi S, Coll MJ, Chabas A, et al. Mutation 1091delC is highly prevalent in Spanish Sanfilippo syndrome type A patients. Hum Mutat 1998;12:274-9.
DOI
|
| 4 |
Gabrielli O, Coppa GV, Bruni S, Villani GR, Pontarelli G, Di Natale P. An adult Sanfilippo type A patient with homozygous mutation R206P in the sulfamidase gene. Am J Med Genet A 2005;133a:85-9.
DOI
|
| 5 |
Weber B, Blanch L, Clements PR, Scott HS, Hopwood JJ. Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B). Hum Mol Genet 1996;5:771-7.
DOI
|
| 6 |
Yogalingam G, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications. Hum Mutat 2001;18:264-81.
DOI
|
| 7 |
Kim YE, Park HD, Jang MA, Ki CS, Lee SY, Kim JW, et al. A novel mutation (c.200T>C) in the NAGLU gene of a Korean patient with mucopolysaccharidosis IIIB. Ann Lab Med 2013;33:221-4.
DOI
|
| 8 |
Kim JH, Chi YH, Kim GH, Yoo HW, Lee JH. Long-term clinical course of a patient with mucopolysaccharidosis type IIIB. Korean J Pediatr 2016;59:S37-40.
DOI
|
| 9 |
Hrebicek M, Mrazova L, Seyrantepe V, Durand S, Roslin NM, Noskova L, et al. Mutations in TMEM76* cause mucopolysaccharidosis IIIC (Sanfilippo C syndrome). Am J Hum Genet 2006;79:807-19.
DOI
|
| 10 |
Fan X, Tkachyova I, Sinha A, Rigat B, Mahuran D. Characterization of the biosynthesis, processing and kinetic mechanism of action of the enzyme deficient in mucopolysaccharidosis IIIC. PLoS One 2011;6:e24951.
DOI
|
| 11 |
Canals I, Elalaoui SC, Pineda M, Delgadillo V, Szlago M, Jaouad IC, et al. Molecular analysis of Sanfilippo syndrome type C in Spain: seven novel HGSNAT mutations and characterization of the mutant alleles. Clin Genet 2011;80:367-74.
DOI
|
| 12 |
Huh HJ, Seo JY, Cho SY, Ki CS, Lee SY, Kim JW, et al. The first Korean case of mucopolysaccharidosis IIIC (Sanfilippo syndrome type C) confirmed by biochemical and molecular investigation. Ann Lab Med 2013;33:75-9.
DOI
|
| 13 |
Buhrman D, Thakkar K, Poe M, Escolar ML. Natural history of Sanfilippo syndrome type A. J Inherit Metab Dis 2014;37:431-7.
DOI
|
| 14 |
Meyer A, Kossow K, Gal A, Muhlhausen C, Ullrich K, Braulke T, et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 2007;120:e1255-61.
DOI
|
| 15 |
Wraith JE, Danks DM, Rogers JG. Mild Sanfilippo syndrome: a further cause of hyperactivity and behavioural disturbance. Med J Aust 1987;147:450-1.
|
| 16 |
Bax MC, Colville GA. Behaviour in mucopolysaccharide disorders. Arch Dis Child 1995;73:77-81.
DOI
|
| 17 |
Colville GA, Watters JP, Yule W, Bax M. Sleep problems in children with Sanfilippo syndrome. Dev Med Child Neurol 1996;38:538-44.
|
| 18 |
Fraser J, Wraith JE, Delatycki MB. Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians. Clin Genet 2002;62:418-21.
DOI
|
| 19 |
Stone JE. Urine analysis in the diagnosis of mucopolysaccharide disorders. Ann Clin Biochem 1998;35 (Pt 2):207-25.
DOI
|
| 20 |
Chuang CK, Lin HY, Wang TJ, Tsai CC, Liu HL, Lin SP. A modified liquid chromatography/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis 2014;9:135.
DOI
|
| 21 |
Fuller M, Rozaklis T, Ramsay SL, Hopwood JJ, Meikle PJ. Disease-specific markers for the mucopolysaccharidoses. Pediatr Res 2004;56:733-8.
DOI
|
| 22 |
Karpova EA, Voznyi Ya V, Keulemans JL, Hoogeveen AT, Winchester B, Tsvetkova IV, et al. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA). J Inherit Metab Dis 1996;19:278-85.
DOI
|
| 23 |
Marsh J, Fensom AH. 4-Methylumbelliferyl alpha-Nacetylglucosaminidase activity for diagnosis of Sanfilippo B disease. Clin Genet 1985;27:258-62.
|
| 24 |
Voznyi Ya V, Karpova EA, Dudukina TV, Tsvetkova IV, Boer AM, Janse HC, et al. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease C (MPS III C). J Inherit Metab Dis 1993;16:465-72.
DOI
|
| 25 |
He W, Voznyi Ya V, Boer AM, Kleijer WJ, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type D (MPS IIID). J Inherit Metab Dis 1993;16:935-41.
DOI
|
| 26 |
Fensom AH, Benson PF. Recent advances in the prenatal diagnosis of the mucopolysaccharidoses. Prenat Diagn 1994;14:1-12.
DOI
|
| 27 |
Dietz HC. New therapeutic approaches to mendelian disorders. N Engl J Med 2010;363:852-63.
DOI
|
| 28 |
Rozaklis T, Beard H, Hassiotis S, Garcia AR, Tonini M, Luck A, et al. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Exp Neurol 2011;230:123-30.
DOI
|
| 29 |
Hemsley KM, King B, Hopwood JJ. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol Genet Metab 2007;90:313-28.
DOI
|
| 30 |
Savas PS, Hemsley KM, Hopwood JJ. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab 2004;82:273-85.
DOI
|
| 31 |
Sivakumur P, Wraith JE. Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J Inherit Metab Dis 1999;22:849-50.
DOI
|
| 32 |
Welling L, Marchal JP, van Hasselt P, van der Ploeg AT, Wijburg FA, Boelens JJ. Early umbilical cord blood-derived stem cell transplantation does not prevent neurological deterioration in mucopolysaccharidosis type III. JIMD Rep 2015;18:63-8.
|
| 33 |
Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 2013.
|
| 34 |
Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, et al. Intracerebral administration of adenoassociated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther 2014;25:506-16.
DOI
|
| 35 |
Guffon N, Bin-Dorel S, Decullier E, Paillet C, Guitton J, Fouilhoux A. Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, doubleblind, placebo-controlled study. J Pediatr 2011;159:838-44.e1.
DOI
|
| 36 |
Suzuki Y. Emerging novel concept of chaperone therapies for protein misfolding diseases. Proc Jpn Acad Ser B Phys Biol Sci 2014;90:145-62.
DOI
|
| 37 |
Feldhammer M, Durand S, Pshezhetsky AV. Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C. PLoS One 2009;4:e7434.
DOI
|
| 38 |
Scott HS, Blanch L, Guo XH, Freeman C, Orsborn A, Baker E, et al. Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat Genet 1995;11:465-7.
DOI
|
| 39 |
Muenzer J. Mucopolysaccharidoses. Adv Pediatr 1986;33: 269-302.
|
| 40 |
Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995;72:263-7.
DOI
|
| 41 |
Zhao HG, Li HH, Bach G, Schmidtchen A, Neufeld EF. The molecular basis of Sanfilippo syndrome type B. Proc Natl Acad Sci U S A 1996;93:6101-5.
DOI
|
| 42 |
Fan X, Zhang H, Zhang S, Bagshaw RD, Tropak MB, Callahan JW, et al. Identification of the gene encoding the enzyme deficient in mucopolysaccharidosis IIIC (Sanfilippo disease type C). Am J Hum Genet 2006;79:738-44.
DOI
|
| 43 |
Robertson DA, Callen DF, Baker EG, Morris CP, Hopwood JJ. Chromosomal localization of the gene for human glucosamine-6-sulphatase to 12q14. Hum Genet 1988;79:175-8.
DOI
|
| 44 |
Ruijter GJ, Valstar MJ, van de Kamp JM, van der Helm RM, Durand S, van Diggelen OP, et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Mol Genet Metab 2008;93:104-11.
DOI
|
| 45 |
Shapiro EG, Nestrasil I, Delaney KA, Rudser K, Kovac V, Nair N, et al. A prospective natural history study of mucopolysaccharidosis type IIIA. J Pediatr 2016;170:278-87.e1-4.
DOI
|
| 46 |
White KK, Karol LA, White DR, Hale S. Musculoskeletal manifestations of Sanfilippo syndrome (mucopolysaccharidosis type III). J Pediatr Orthop 2011;31:594-8.
DOI
|
| 47 |
Heron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C, et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A 2011;155a:58-68.
|
| 48 |
Valstar MJ, Bertoli-Avella AM, Wessels MW, Ruijter GJ, de Graaf B, Olmer R, et al. Mucopolysaccharidosis type IIID: 12 new patients and 15 novel mutations. Hum Mutat 2010;31:E1348-60.
|
| 49 |
Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJ, Wevers RA, et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 2010;68:876-87.
DOI
|
| 50 |
Valstar MJ, Bruggenwirth HT, Olmer R, Wevers RA, Verheijen FW, Poorthuis BJ, et al. Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis 2010;33:759-67.
DOI
|
| 51 |
Nidiffer FD, Kelly TE. Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study. J Ment Defic Res 1983;27 (Pt 3):185-203.
|
| 52 |
van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 1981;20:152-60.
|
| 53 |
Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 2006;60:309-14.
DOI
|
| 54 |
Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 2007;92:115-21.
DOI
|
| 55 |
Roberts AL, Fletcher JM, Moore L, Byers S. Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA. Mol Genet Metab 2010;101:208-13.
DOI
|
| 56 |
Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5.
DOI
|
| 57 |
Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Wegrzyn A, et al. Genisteinmediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 2006;14:846-52.
DOI
|
| 58 |
Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE, et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010;5:e14192.
DOI
|
| 59 |
Malinova V, Wegrzyn G, Narajczyk M. The use of elevated doses of genistein-rich soy extract in the gene expressiontargeted isoflavone therapy for Sanfilippo disease patients. JIMD Rep 2012;5:21-5.
|
| 60 |
Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007;6:765-72.
DOI
|
| 61 |
Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6.
DOI
|
| 62 |
Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28:1011-7.
DOI
|
| 63 |
Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A 2009;149a:960-4.
DOI
|
| 64 |
Cleary MA, Wraith JE. Management of mucopolysaccharidosis type III. Arch Dis Child 1993;69:403-6.
DOI
|
| 65 |
Gilkes JA, Bloom MD, Heldermon CD. Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes. Mol Genet Metab Rep 2016;6:48-54.
DOI
|
| 66 |
Sohn WY, Lee JH, Paik KH, Kwon EK, Kim AH, Jin DK. Clinical and laboratory features of Korean mucopolysaccharidoses (MPSs). Korean J Pediatr 2005;48:1132-8.
|
| 67 |
Winner LK, Beard H, Hassiotis S, Lau AA, Luck AJ, Hopwood JJ, et al. A preclinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome. Hum Gene Ther 2016;27:363-75.
DOI
|
| 68 |
King B, Hassiotis S, Rozaklis T, Beard H, Trim PJ, Snel MF, et al. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA. J Neurochem 2016;137:409-22.
DOI
|
| 69 |
Coutinho MF, Santos JI, Alves S. Less is more: Substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci 2016;17.
|
| 70 |
Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
DOI
|
| 71 |
Karageorgos LE, Guo XH, Blanch L, Weber B, Anson DS, Scott HS, et al. Structure and sequence of the human sulphamidase gene. DNA Res 1996;3:269-71.
DOI
|
| 72 |
Canals I, Beneto N, Cozar M, Vilageliu L, Grinberg D. EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome. Sci Rep 2015;5:13654.
DOI
|
| 73 |
Matos L, Canals I, Dridi L, Choi Y, Prata MJ, Jordan P, et al. Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations. Orphanet J Rare Dis 2014;9:180.
DOI
|
| 74 |
Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991;60:443-75.
DOI
|
| 75 |
Cooper DN, Ball EV, Stenson PD, Phillips AD, Evans K, Heywood S, et al. The human gene mutation database [Internet]. Cardiff University, 2017 [cited 2017 May 13]. Available from: http://www.hgmd.org.
|
| 76 |
Bunge S, Ince H, Steglich C, Kleijer WJ, Beck M, Zaremba J, et al. Identification of 16 sulfamidase gene mutations including the common R74C in patients with mucopolysaccharidosis type IIIA (Sanfilippo A). Hum Mutat 1997;10:479-85.
DOI
|
webmaster
